Management of high-grade neuroendocrine neoplasms: impact of functional imaging
Endocrine-Related Cancer · 2025
DOI: 10.1530/erc-24-0231 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Endocrine-Related Cancer, 2025. Verfasst von O Islam und 20 weiteren Autor:innen. Hauptthemen laut MEDLINE: Intestinal Neoplasms, Neuroendocrine Tumors, Pancreatic Neoplasms, Stomach Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 44 Literaturangaben.
Abstract (Originalsprache)
Gastroenteropancreatic neuroendocrine neoplasms (GEP NEN) exhibit substantial biological heterogeneity, impacting clinical management and outcomes. In 2019, the WHO subdivided the grade 3 (G3) neuroendocrine neoplasms (NEN) characterised by Ki-67 > 20% into the well-differentiated G3 neuroendocrine tumour (NET) and G3 poorly differentiated neuroendocrine carcinoma (NEC) subgroups. Since this update, questions about the prognostic implications and best treatment strategies for NET G3 and NEC remain. Therefore, we initiated a real-world retrospective observational cohort study using data from 225 NEC and 58 NET G3 patients treated in Belgium. Analysis of patient and tumour characteristics and the effect of survival was conducted. Most frequent primary locations were pancreatic (32.9%) and colorectal (21.5%), and 71.8% was diagnosed with stage IV disease. Median overall survival (mOS) was higher in NET G3 (41.3 months (m)) compared to NEC (13.2m). Of those who underwent functional imaging, fluorodeoxyglucose–positron emission tomography (18F-FDG-PET) imaging was positive in 90.6 and 95.6% of the NET G3 and NEC patients, respectively, and somatostatin receptor (SSTR) expression was seen in 97.4 and 66.0%, respectively. The latter was linked to better mOS, suggesting the added value of performing both SSTR imaging and 18F-FDG-PET for high-grade (HG) NEN to provide prognostic information and to possibly expand therapeutic options, which are currently reserved for lower-grade NEN patients. Moreover, while debated, in our population, primary surgery was performed in 92 and 73.5% of locoregional NET G3 and NEC cases, respectively, indicating that surgery can be considered in locoregional setting. Finally, platinum–etoposide was the predominant first-line treatment in metastatic NEC, with no significant survival difference between carboplatin and cisplatin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
ORCID-Profile: O Islam, I Borbath, T Vandamme
Zitieren
APA
Islam, O., Sarti, K., Verbruggen, L., Vandersmissen, V., Bulcke, K. V., Annys, L., Verslype, C., Van Laethem, J. L., Kalantari, H. R., Janssens, J., Hendlisz, A., Cuyle, P. J., Demolin, G., Decaestecker, J., Geboes, K., Coche, J. C., Van Ongeval, J., Lybaert, W., Peeters, M., …, & Vandamme, T. (2025). Management of high-grade neuroendocrine neoplasms: impact of functional imaging. Endocrine-Related Cancer. https://doi.org/10.1530/erc-24-0231
Vancouver
Islam O, Sarti K, Verbruggen L, Vandersmissen V, Bulcke KV, Annys L, et al. Management of high-grade neuroendocrine neoplasms: impact of functional imaging. Endocrine-Related Cancer. 2025. doi:10.1530/erc-24-0231
BibTeX
@article{Islam2025,
author = {Islam, O and Sarti, K and Verbruggen, L and Vandersmissen, V and Bulcke, K Vanden and Annys, L and Verslype, C and Van Laethem, J L and Kalantari, H Rezaei and Janssens, J and Hendlisz, A and Cuyle, P J and Demolin, G and Decaestecker, J and Geboes, K and Coche, J C and Van Ongeval, J and Lybaert, W and Peeters, M and Borbath, I and Vandamme, T},
title = {Management of high-grade neuroendocrine neoplasms: impact of functional imaging},
journal = {Endocrine-Related Cancer},
year = {2025},
doi = {10.1530/erc-24-0231}
}
EUVIMED